CO5261608A1 - Composicion farmaceutica en forma de una suspension que comprende oxcarbazepina - Google Patents

Composicion farmaceutica en forma de una suspension que comprende oxcarbazepina

Info

Publication number
CO5261608A1
CO5261608A1 CO00094330A CO00094330A CO5261608A1 CO 5261608 A1 CO5261608 A1 CO 5261608A1 CO 00094330 A CO00094330 A CO 00094330A CO 00094330 A CO00094330 A CO 00094330A CO 5261608 A1 CO5261608 A1 CO 5261608A1
Authority
CO
Colombia
Prior art keywords
suspension
oxcarbazepine
composition according
milliliter
grams
Prior art date
Application number
CO00094330A
Other languages
English (en)
Inventor
Sigg Juergen
Michael Billington
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10866648&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO5261608(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CO5261608A1 publication Critical patent/CO5261608A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Una composición farmacéutica en la forma de una suspensión que comprende oxcarbazepina, y que tiene, cuando se agita, una viscosidad en la escala de 5 a 52 mPa. s. Una composición farmacéutica en la forma de una suspensión que comprende oxcarbazepina y una mezcla de carboximetilcelulosa y celulosa microcristalina, en una escala del 1.25 al 1.95 por ciento (gramos/mililitro)de la composición total. Una composición de acuerdo con la reivindicación 2, en donde la proporción de la carboximetilcelulosa a la celulosa microcristalina en la mezcla es de 1: 5 a 1:12. Una composición de acuerdo con la reivindicación 2 ó 3, en donde la carboximetilcelulosa en la mezcla es una sal sódica. Una composición de acuerdo con cualquiera de las reivindicaciones 1 a 4, la cual comprende un antioxidante. Una composición de acuerdo con la reivindicación 5, en donde el antioxidante es ácido ascórbico. Una composición de acuerdo con la reivindicación 5 ó 6, en donde el antioxidante está presente en una escala del 0.75 al 2 por ciento (gramos/mililitro)de la composición total. Una composición de acuerdo con cualquiera de las reivindicaciones anteriores, que tiene un pH en la escala de 2 a 4.Una composición de acuerdo con cualquiera de las reivindicaciones anteriores, la cual comprende oxcarbazepina en una cantidad del 1 al 20 por ciento (gramos/mililitro). Una composición farmacéutica en la forma de una suspensión que comprende oxcarbazepina y menos del 0.5 por ciento (gramos/mililitro)de hidroxietilcelulosa. Un recipiente que tiene un volumen de llenado de aproximadamente 50 mililitros a aproximadamente 300 mililitros, el cual comprende una suspensión de oxcarbazepina de acuerdo con cualquiera de las reivindicaciones anteriores, y una jeringa dosificadora adaptada para ajustarse a este recipiente. Una composición farmacéutica en la forma de una suspensión tixotrópica oral que comprende el 6 por ciento (gramos/mililitro)de oxcarbazepina, y que tiene, cuando se agita, una viscosidad en la escala de 5 a 52 mPa. s.
CO00094330A 1999-12-20 2000-12-12 Composicion farmaceutica en forma de una suspension que comprende oxcarbazepina CO5261608A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9930058.4A GB9930058D0 (en) 1999-12-20 1999-12-20 Organic compounds

Publications (1)

Publication Number Publication Date
CO5261608A1 true CO5261608A1 (es) 2003-03-31

Family

ID=10866648

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00094330A CO5261608A1 (es) 1999-12-20 2000-12-12 Composicion farmaceutica en forma de una suspension que comprende oxcarbazepina

Country Status (34)

Country Link
US (1) US8119148B2 (es)
EP (2) EP1239832B1 (es)
JP (2) JP4588281B2 (es)
KR (2) KR100496368B1 (es)
CN (1) CN1216594C (es)
AR (1) AR030175A1 (es)
AT (1) ATE269694T1 (es)
AU (1) AU777619B2 (es)
BE (2) BE1013706A5 (es)
BR (1) BR0016524A (es)
CA (1) CA2390029C (es)
CO (1) CO5261608A1 (es)
CZ (1) CZ302737B6 (es)
DE (1) DE60011809T2 (es)
DK (1) DK1239832T3 (es)
ES (1) ES2223641T3 (es)
FR (1) FR2802423B1 (es)
GB (1) GB9930058D0 (es)
HK (1) HK1050474A1 (es)
HU (1) HU226486B1 (es)
IL (2) IL149498A0 (es)
IT (1) ITMI20002717A1 (es)
MX (1) MXPA02006142A (es)
MY (1) MY126868A (es)
NO (1) NO331990B1 (es)
NZ (1) NZ518755A (es)
PE (1) PE20010933A1 (es)
PL (1) PL201331B1 (es)
PT (1) PT1239832E (es)
RU (1) RU2277912C2 (es)
SK (1) SK287553B6 (es)
TR (2) TR200201459T2 (es)
WO (1) WO2001045671A2 (es)
ZA (1) ZA200204863B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9930058D0 (en) * 1999-12-20 2000-02-09 Novartis Ag Organic compounds
DE10224086A1 (de) * 2002-05-31 2003-12-11 Bayer Ag Pharmazeutische Zubereitungen zur oralen Anwendung enthaltend wirkstoffbeladene Ionentauscherharze sowie strukturviskose Gelbildner als Verdicker
WO2004026263A2 (en) 2002-09-20 2004-04-01 Fmc Corporation Cosmetic composition containing microcrystalline cellulose
GB0221956D0 (en) * 2002-09-20 2002-10-30 Novartis Ag Organic compounds
US20060270658A1 (en) 2003-09-03 2006-11-30 Donald Manning Use of oxcarbazepine for the treatment of diabetic neuropathic pain and the improvement of sleep
US20060252745A1 (en) 2005-05-06 2006-11-09 Almeida Jose L D Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
WO2007007182A2 (en) * 2005-07-08 2007-01-18 Aurobindo Pharma Limited Solid and liquid dosage forms of an antiepileptic agent
EP1906937B1 (en) 2005-07-22 2016-10-19 Rubicon Research Pvt Ltd. Novel dispersible tablet composition
AU2007242984B2 (en) * 2006-04-26 2012-11-08 Supernus Pharmaceuticals Inc. Controlled released preparations of oxcarbazepine having sigmoidal release profile
GB0700773D0 (en) 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies
KR20080076667A (ko) * 2007-02-15 2008-08-20 주식회사 중외제약 요변성 약학 조성물
KR20120094473A (ko) * 2009-09-10 2012-08-24 바이알 - 포르텔라 앤드 씨에이 에스에이 에슬리카바제핀 아세테이트의 경구용 현탁액 제제
CN104288104A (zh) * 2014-09-24 2015-01-21 万特制药(海南)有限公司 奥卡西平干混悬剂及其制备方法
US10973783B2 (en) 2015-12-30 2021-04-13 Adamas Pharmaceuticals, Inc. Methods and compositions for the treatment of seizure-related disorders
CN109010322A (zh) * 2018-07-13 2018-12-18 山东达因海洋生物制药股份有限公司 一种包含奥卡西平的口腔分散膜剂及其制备方法
CN115487145B (zh) * 2022-10-10 2023-09-01 上海奥科达医药科技股份有限公司 一种奥卡西平口服混悬液及其制备方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH500196A (de) 1969-03-10 1970-12-15 Ciba Geigy Ag Verfahren zur Herstellung von neuen Azepinderivaten
US4004029A (en) * 1974-05-13 1977-01-18 The Upjohn Company Compositions and method for treating epilepsy and convulsions
US4431641A (en) * 1980-10-17 1984-02-14 Ciba-Geigy Corporation Pharmaceutical compositions having antiepileptic and antineuralgic action
RO81639A2 (ro) * 1981-02-27 1983-06-01 Intreprinderea De Medicamente "Biofarm",Ro Procedeu de obtinere a unei pulberi suspendabile oxrale de ampicilina
CH649080A5 (de) * 1981-04-16 1985-04-30 Ciba Geigy Ag 5h-dibenz(b,f)azepin-5-carboxamide als mittel zur prophylaxe und behandlung von zerebraler leistungsinsuffizienz.
US4427681A (en) * 1982-09-16 1984-01-24 Richardson-Vicks, Inc. Thixotropic compositions easily convertible to pourable liquids
JPS60204713A (ja) 1984-03-30 1985-10-16 Zenyaku Kogyo Kk 水性懸濁組成物
US4693901A (en) * 1985-12-10 1987-09-15 Cardinal Biological, Ltd. Shelf stable dairylike products
GB8618847D0 (en) * 1986-08-01 1986-09-10 Smith Kline French Lab Pharmaceutical formulations
IL86211A (en) * 1987-05-04 1992-03-29 Ciba Geigy Ag Oral forms of administration for carbamazepine in the forms of stable aqueous suspension with delayed release and their preparation
IL90245A (en) * 1988-05-11 1994-04-12 Glaxo Group Ltd Resin adsorption containing ranitidine together with synthetic resin replaces cations, its preparation and pharmaceutical preparations containing it
ES2054089T3 (es) 1988-11-10 1994-08-01 Ciba Geigy Ag Formulaciones orales liquidas.
GB9102579D0 (en) 1991-01-24 1991-03-27 Glaxo Group Ltd Compositions
US5272137A (en) * 1992-02-14 1993-12-21 Mcneil-Pfc, Inc. Aqueous pharmaceutical suspension for pharmaceutical actives
GB9219524D0 (en) * 1992-09-15 1992-10-28 Smithkline Beecham Plc Novel composition
FR2699077B1 (fr) * 1992-12-16 1995-01-13 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement de lésions neurologiques liées à des traumatismes.
JP3254219B2 (ja) * 1993-01-19 2002-02-04 ワーナー−ランバート・コンパニー 安定な経口用のｃｉ−９８１製剤およびその製法
FR2702148B1 (fr) 1993-03-05 1995-04-07 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement du neuro-sida.
FR2702149B1 (fr) 1993-06-03 1995-04-07 Rhone Poulenc Rorer Sa Application de la lamotrigine dans le traitement du neuro-sida.
FR2702151B1 (fr) 1993-06-03 1995-04-07 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement du neuro-sida.
US5472714A (en) * 1993-09-08 1995-12-05 Ciba-Geigy Corporation Double-layered oxcarbazepine tablets
US5646131A (en) * 1994-02-22 1997-07-08 The Arab Company For Drug Industries And Medical Applicances (Acdima) Method for solubilizing drugs using cyclodextrins and carboxylic acids
ZA953078B (en) * 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies
NZ295132A (en) 1994-10-14 1998-06-26 Janssen Pharmaceutica Nv Sabeluzole aqueous suspension having ph from 8 to 10
DE4443966A1 (de) * 1994-12-09 1996-06-13 Basf Ag Thermoplastische Formmassen
PT101732B (pt) 1995-06-30 1997-12-31 Portela & Ca Sa Novas di-hidrodibenzo<b,f>azepinas substituidas processo para a sua preparacao composicoes farmaceuticas que as contem e utilizacao dos novos compostos na preparacao de composicoes farmaceuticas empregues em doencas do sistema nervoso
IT1277663B1 (it) 1995-09-28 1997-11-11 Crinos Industria Farmaco Sospensioni acquose stabili di mesalazina per uso topico
PT101876B (pt) * 1996-05-27 1999-09-30 Portela & Ca Sa Novos derivados de 10,11-di-hidro-10-oxo-5h-dibenzo(b,f)azepina-5-carboxamida
IT1286496B1 (it) 1996-11-20 1998-07-15 Leetrim Ltd Dublin Composizione farmaceutica orale ad attivita' antipiretica,analgesica ed antiinfiammatoria
US6037380A (en) * 1997-04-11 2000-03-14 Fmc Corporation Ultra-fine microcrystalline cellulose compositions and process
US6146876A (en) * 1999-06-11 2000-11-14 Millennium Pharmaceuticals, Inc. 22025, a novel human cyclic nucleotide phosphodiesterase
GB9930058D0 (en) * 1999-12-20 2000-02-09 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
AU777619B2 (en) 2004-10-21
GB9930058D0 (en) 2000-02-09
AR030175A1 (es) 2003-08-13
TR200201459T2 (tr) 2002-09-23
PL201331B1 (pl) 2009-03-31
IL149498A (en) 2011-05-31
NO20022849D0 (no) 2002-06-14
BR0016524A (pt) 2002-09-24
US8119148B2 (en) 2012-02-21
US20030004155A1 (en) 2003-01-02
EP1239832B1 (en) 2004-06-23
DE60011809T2 (de) 2005-06-30
DE60011809D1 (en) 2004-07-29
MXPA02006142A (es) 2002-12-05
CA2390029A1 (en) 2001-06-28
CN1216594C (zh) 2005-08-31
EP1239832A2 (en) 2002-09-18
SK8652002A3 (en) 2002-12-03
CN1411367A (zh) 2003-04-16
RU2277912C2 (ru) 2006-06-20
FR2802423A1 (fr) 2001-06-22
RU2002119210A (ru) 2004-02-27
CZ302737B6 (cs) 2011-10-12
KR100496368B1 (ko) 2005-06-21
MY126868A (en) 2006-10-31
WO2001045671A3 (en) 2002-02-21
JP2003518036A (ja) 2003-06-03
IL149498A0 (en) 2002-11-10
JP4588281B2 (ja) 2010-11-24
PT1239832E (pt) 2004-10-29
CZ20022138A3 (cs) 2002-09-11
NO331990B1 (no) 2012-05-21
HUP0203782A3 (en) 2005-01-28
ZA200204863B (en) 2003-03-17
DK1239832T3 (da) 2004-08-09
BE1014502A5 (fr) 2003-11-04
PL355535A1 (en) 2004-05-04
KR20040098034A (ko) 2004-11-18
HK1050474A1 (en) 2003-06-27
AU2511801A (en) 2001-07-03
EP1437127A1 (en) 2004-07-14
JP2006312651A (ja) 2006-11-16
NO20022849L (no) 2002-06-14
BE1013706A5 (fr) 2002-06-04
HU226486B1 (en) 2009-03-02
WO2001045671A2 (en) 2001-06-28
TR200402419T4 (tr) 2004-12-21
ATE269694T1 (de) 2004-07-15
FR2802423B1 (fr) 2005-03-25
CA2390029C (en) 2010-01-26
NZ518755A (en) 2004-04-30
HUP0203782A2 (hu) 2003-03-28
SK287553B6 (sk) 2011-01-04
ES2223641T3 (es) 2005-03-01
PE20010933A1 (es) 2001-09-17
KR20020062658A (ko) 2002-07-26
ITMI20002717A1 (it) 2002-06-15

Similar Documents

Publication Publication Date Title
CO5261608A1 (es) Composicion farmaceutica en forma de una suspension que comprende oxcarbazepina
MXPA03000190A (es) Composicion para el suministro del factor de crecimiento hamtopoyetico.
BRPI0407845A (pt) formulação intranasal de rotigotina
BR0211736A (pt) Formulação para suspensão oral estabilizada
HUP0302283A2 (hu) Javított injektálhatósággal rendelkező injektálható szuszpenziók előállítása
PE84899A1 (es) Formulaciones farmaceuticas que contienen voriconazol
TR200002995T2 (tr) Folik asit ihtiva eden farmasötik bileşimler, bununla ilgili yöntemler ve uygulama sistemleri
HUP0300409A2 (hu) Antiadhezív szénhidrátokat tartalmazó gyógyszerkészítmények és alkalmazásuk
PL366314A1 (en) Pharmaceutical compositions
ES2570856T3 (es) Composiciones oftálmicas que contienen una combinación sinérgica de dos polímeros
BR9810658A (pt) Composições farmacêuticas contendo hemissulfato de eletriptano e cafeìna.
TW200621745A (en) Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents
PL370068A1 (en) Orally administered liquid compositions comprising guaifenesin and a polyoxyalkylene block copolymer
PE34496A1 (es) Formulacion de analogo de insulina monomerico
WO2007143652A3 (en) Chewable soft gelatin capsules
EA200970047A1 (ru) Водные суспензии тмс278
BRPI0518191A (pt) métodos e composições para reduzir a toxicidade de um composto farmacêutico
TW200501965A (en) Highly pure fondaparinux sodium composition,process for preparing said composition and pharmaceutical compositions containing it as active principle
MEP14508A (en) Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels
ES2720954T3 (es) Formulaciones estabilizadas de estatina
AR038947A1 (es) Suspension oral de sabor agradable y metodo
DE69912262D1 (de) Retinolhaltiges arzneimittel kompatibel mit weichgelatinekapseln
AR046315A1 (es) Un sistema de dos pasos para mejorar las caracteristicas iniciales y finales de un material biologico
MY135548A (en) Aqueous preparation containing oligopeptides and etherified cyclodextrin
DE60223542D1 (de) Zusammensetzung mit fulvestrant

Legal Events

Date Code Title Description
FC Application refused